<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05257694</url>
  </required_header>
  <id_info>
    <org_study_id>S2022-002</org_study_id>
    <nct_id>NCT05257694</nct_id>
  </id_info>
  <brief_title>Clinical Decision and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning</brief_title>
  <official_title>A Deep Learning Model Based on Contrast-enhanced Ultrasound to Aid Clinical Decisions Prognosis Prediction of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ping Liang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the&#xD;
      prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collecting CEUS and clinical data of HCC from different institutions retrospectively.&#xD;
&#xD;
      Developing a deep learning model based on CEUS to predict the prognosis of HCC. Developing a&#xD;
      deep learning model based on CEUS to choose a better operation (ablation or surgery) of HCC&#xD;
      patients.&#xD;
&#xD;
      Then, validating the deep learning model in the prospective data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival (RFS)</measure>
    <time_frame>Immediately after the surgery or ablation</time_frame>
    <description>Recurrence-free survival is defined as the time elapsed between a predefined point in time (the date of diagnosis, randomization or the intervention) and any recurrence (local, regional, or distant) or death due to any cause (death is an event).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>Immediately after the surgery or ablation</time_frame>
    <description>Recurrence included local tumor progression, regional recurrence, or distant recurrence.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Contrast-enhanced Ultrasound</condition>
  <condition>Prognosis</condition>
  <condition>Surgery</condition>
  <condition>Ablation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery or Ablation</description>
    <other_name>Ablation (Microwave ablation or Radiofrequency ablation)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with HCC corresponding to Ia, Ib, IIa stage (China liver cancer staging) who&#xD;
        undergo resection or ablation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with HCC (Ia, Ib, IIa stage) China liver cancer staging who underwent&#xD;
             resection or ablation&#xD;
&#xD;
          -  without macro-vascular invasion&#xD;
&#xD;
          -  Child-Pugh A/B grade&#xD;
&#xD;
          -  HCC is proved by pathological examination or two enhanced imaging&#xD;
&#xD;
          -  CEUS (Sonovue or Sonozoid) images are performed two weeks before the operation&#xD;
&#xD;
          -  CEUS images are included in at least three stages (Arterial phase, Portal phase, and&#xD;
             Late phase)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  postop follow-up loss or expired less than 3 months&#xD;
&#xD;
          -  patients with co-malignancy&#xD;
&#xD;
          -  poor images quality for analyzing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ping Liang, Dr.</last_name>
    <phone>+86 10 66939530</phone>
    <email>liangping301@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jiapeng wu, Dr.</last_name>
    <phone>+86 13079692188</phone>
    <email>wjpdabao@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Liang, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>February 13, 2022</study_first_submitted>
  <study_first_submitted_qc>February 24, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2022</study_first_posted>
  <last_update_submitted>February 24, 2022</last_update_submitted>
  <last_update_submitted_qc>February 24, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Ping Liang</investigator_full_name>
    <investigator_title>Chief of department of interventional ultrasound</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

